ATNF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATNF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. 180 Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0. 180 Life Sciences's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.
As of today (2024-12-13), 180 Life Sciences's share price is $1.93. 180 Life Sciences's Median PS Value is $0.00. Therefore, 180 Life Sciences's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for 180 Life Sciences's Median PS Value or its related term are showing as below:
The historical data trend for 180 Life Sciences's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
180 Life Sciences Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Median PS Value | - | - | - | - | - |
180 Life Sciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, 180 Life Sciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, 180 Life Sciences's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where 180 Life Sciences's Price-to-Median-PS-Value falls into.
180 Life Sciences's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 0 | * | ||
= | 0.00 |
10-Year Median PS Ratio is .
180 Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
180 Life Sciences (NAS:ATNF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
180 Life Sciences's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 1.93 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of 180 Life Sciences's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
James N. Woody | director, officer: Chief Executive Officer | C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Marc Feldmann | director | 5 DURHAM TERRACE, LONDON X0 W25PB |
Lawrence Steinman | director | 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121 |
Mcgovern Jr. Donald A. | director | C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606 |
Quan Anh Vu | officer: COO / Chief Business Officer | 22616 ERWIN STREET, WOODLAND HILLS CA 91367 |
Ozan Pamir | officer: Interim CFO | 2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115 |
Pamela G Marrone | director | C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618 |
Teresa Deluca | director | 40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215 |
Russell T Ray | director | 2525 DUPONT DR, IRVINE CA 92612 |
Knuettel Ii Francis | director | 205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701 |
Marlene Krauss | director, 10 percent owner, officer: Chief Executive Officer | C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022 |
Lawrence Marshall Gold | director | 830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025 |
Jonathan B. Rothbard | officer: Chief Scientific Officer | 501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105 |
Shoshana Shendelman | director | C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173 |
Richard W Barker | director | 290 COMMONWEALTH AVENUE #17, BOSTON MA 02115 |
From GuruFocus
By Marketwired • 08-07-2023
By ACCESSWIRE • 12-04-2024
By PRNewswire PRNewswire • 01-03-2023
By Marketwired • 08-10-2023
By GuruFocus Research GuruFocus Editor • 05-20-2023
By Stock market mentor Stock market mentor • 01-17-2023
By ACCESSWIRE • 10-29-2024
By GuruFocus News • 11-15-2024
By Marketwired • 07-30-2024
By ACCESSWIRE • 10-03-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.